Company profile: Astute Medical
1.1 - Company Overview
Company description
- Provider of diagnostic solutions for high-risk medical conditions via identification and validation of protein biomarkers, focused on community and hospital-acquired acute conditions needing rapid diagnosis and risk assessment. Products include BIOFIRE FILMARRAY Torch, VITEK MS, VIDAS BRAHMS PCT, and BACT/ALERT VIRTUO.
Products and services
- BACT/ALERT® VIRTUO®: A fully automated blood culture system delivering quick detection time and real-time blood volume notifications to streamline laboratory workflows
- BIOFIRE® FILMARRAY® Torch: A PCR-based, CLIA-moderate compatible platform that tests comprehensive groupings of targets and delivers results in about an hour
- VIDAS® B•R•A•H•M•S PCT™: A rapid-turnaround system aiding PCT-guided antibiotic therapy by producing results in 20 minutes to help optimize patient management
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Astute Medical
Lexicon Pharmaceuticals
HQ: United States
Website
- Description: Provider of precise medicines for human disease, including INPEFA (sotagliflozin), a once-daily oral tablet that reduces the risk of cardiovascular death, heart failure hospitalization and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. Pipeline includes LX9211 for DPNP (AAK1) and sotagliflozin for type 1 diabetes (US regulatory) and HCM (preclinical).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lexicon Pharmaceuticals company profile →
Scribe Therapeutics
HQ: United States
Website
- Description: Provider of CRISPR-based therapeutic platforms and medicines, including X-Editing (XE) technologies for high-activity, specific, deliverable gene editing; CRISPR by Design optimization; ELXR CasX-based epigenetic repressors; in vivo CRISPR genetic medicines (e.g., for sickle cell) with non-viral delivery; and ex vivo natural killer (NK) cell therapies for cancer in collaboration with Sanofi.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Scribe Therapeutics company profile →
QuanDx
HQ: United States
Website
- Description: Provider of life science reagents and molecular diagnostic kits, including the Q-Fusion multiplex system and Q30 screening kit for leukemia fusion genes, Yin-Yang Probes for affordable, multiplexed tests for various diseases, and a High Risk HPV Genotyping Assay detecting 14 types of high-risk HPV with automatic result interpretation in a single tube reaction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full QuanDx company profile →
Airna
HQ: United States
Website
- Description: Provider of RNA editing technologies and therapeutics, including the RESTORE+ RNA editing platform to optimize sequence, chemistry, and delivery for precise RNA editing to treat rare and common diseases. Offers RNA editing therapeutics for alpha-1 antitrypsin deficiency (AATD) and a pipeline addressing diseases with high unmet need.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Airna company profile →
Immuneering
HQ: United States
Website
- Description: Provider of bioinformatics-driven drug discovery developing investigational medicines, including IMM-1-104 targeting RAS-mutant advanced solid tumors with once-daily oral dosing, and IMM-6-415, a Deep Cyclic Inhibitor for RAF or RAS-mutant advanced solid tumors with twice-daily dosing; also maintains an Expanded Access Policy (not currently available).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immuneering company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Astute Medical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Astute Medical
2.2 - Growth funds investing in similar companies to Astute Medical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Astute Medical
4.2 - Public trading comparable groups for Astute Medical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →